BDMD

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. ("Baird Medical" or the "Company") (NASDAQ:BDMD), a medical device company focused on the development and commercialization of minimally invasive treatment technologies, today highlighted key business and operational developments from the third quarter of 2026, including expansion into new international markets, continued physician training initiatives and the addition of irreversible electroporation (IRE) technology to its broader technology portfolio through a strategic partnership. "During the third quarter, we continued to execute on the priorities that we believe will drive Baird Medical’s long-term gr

SCHEDULE 13G - Baird Medical Investment Holdings Ltd (0001982444) (Subject)

6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

424B5 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company") (NASDAQ:BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City. H.C. Wainwright 28th Annual Global Investment ConferenceDate: Wednesday, September 16, 2026Time: 11:30 a.m. ETLocation: Lotte New York Palace Hotel, New York City A live webcast of the presentation will be available through the Investor Relations section of Baird Medical’s website, and a replay will be

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. ("Baird Medical" or the "Company") (NASDAQ:BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today highlighted its participation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, held at the Bella Center Copenhagen. Throughout the congress, Baird Medical showcased its Microwave Ablation (MWA) System to interventional radiologists and healthcare professionals from around the world, providing an opportunity to engage with the global medical community and demons

6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), today announced preliminary unaudited financial results for the six months ended June 30, 2026. Revenue for the first half of 2026 was approximately $9.9 million, an increase of 24.6% over $8.0 million reported for the six months ended June 30, 2025. The increase in revenue was primarily attributable to growth outside of the People’s Republic of China, including in the United States, as well as licensing revenue. Approximately two thirds of revenue for the period was generated from markets outside of the PRC, with Hong Kong and the U.S. being the main contr

NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), announced that the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan ("DRAP"), further supporting the Company’s commercial activities in the country. The registrations build on Baird Medical’s existing presence in Pakistan, where the Company announced regulatory approvals and initial commercial availability at the Armed Forces Institute of Radiology & Imaging ("AFIRI") in January 2026. The latest registrations further expand the regulatory foundat

424B3 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

EFFECT - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

EFFECT - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

Agreement combines Baird Medical's clinical, regulatory, and global commercialization expertise with Alpmed's leadership in IRE technologyCollaboration will advance technology development, global regulatory approvals, commercialization, and clinical adoption across key international markets, including the United States NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company") and Tianjin Yuanshan Medical Technology Co., Ltd., operating under the Alpmed brand ("Alpmed"), a China-based innovator in irreversible electroporation ("IRE") technology, announced the signing of a strategic cooperation agreement to establish

POS AM - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

F-3/A - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

SCHEDULE 13D - Baird Medical Investment Holdings Ltd (0001982444) (Subject)

3 - Baird Medical Investment Holdings Ltd (0001982444) (Issuer)

20-F/A - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

First procedures in two new markets highlight growing global adoption of Baird Medical's minimally invasive microwave ablation technology NEW YORK, June 29, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of the first procedures using its MWA technology in Vietnam and Argentina. In Vietnam, the first clinical case using the Company's MWA technology was completed at Lac Viet Friendship Hospital on June 18. The procedure was performed by Dr. Dinh Xuan H

Enhanced U.S. Presence Centralizes Operations as Company Executes Global Growth StrategyNEW YORK, June 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the relocation of its global headquarters to the U.S., with the establishment of a new corporate office in New York, NY. The relocation follows the December 2025 appointment of Mark Saxton as CEO of Baird Medical's U.S. subsidiary to lead domestic operations, commercial expansion, and market development, establishing a Compan

POS AM - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

F-3 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

SCHEDULE 13G - Baird Medical Investment Holdings Ltd (0001982444) (Subject)

Full year 2025 revenue of $22.5 million, impacted by policy-driven slowdown in Mainland ChinaAdvancing global expansion with appointment of seasoned commercial leader, Mark Saxton, as CEO of Baird Medical U.S. to lead commercial ramp in the United StatesNEW YORK, April 29, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its financial results for the full year ended December 31, 2025 and provided an update on key strategic and operational initiatives.